+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID04496349

Phase IIa Study of APG-115 Alone or with APG-2575 to Treat Relapsed or Refractory T-Cell Prolymphocytic Leukemia and Non-Hodgkins Lymphoma

Led by Ascentage Pharma Group Inc. · Updated on 2025-11-04

78

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the pharmacokinetics, safety, and efficacy of APG-115 alone or combined with APG-2575 in patients with relapsed or refractory T-cell prolymphocytic leukemia T-PLL and non-Hodgkins lymphoma NHL. This phase IIa, open-label trial explores how blocking the MDM2 protein affects tumor suppression by increasing P53 and P21 proteins, aiming to activate cancer cell death. Participants receive APG-115 as a single agent given every other day for two weeks followed by one week off in repeated 21-day cycles. Another group receives APG-115 combined with APG-2575, which is taken orally every day in the same cycle pattern. The study includes dose escalation and expansion phases to assess various dosing regimens of both drugs. During the study, patients will be closely monitored for maximum tolerated doses over 21-day periods. Researchers will evaluate safety, drug effects, and responses while collecting data on how the drugs behave in the body. Participants must meet specific health and laboratory criteria and provide informed consent before joining. The study will continue until May 2027 to gather comprehensive safety and efficacy data.

CONDITIONS

Brief Title

A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL

Research Team

G

Genevieve Frank

J

Jocelyn Budzynski

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here